PAVmed Inc PAVM

NAS: PAVM | ISIN: US70387R1068   30/04/2025
0,725 USD (-0,59%)
(-0,59%)   30/04/2025

1 mei 2025 · PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 · Persbericht

30 april 2025 · Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 · Persbericht

24 april 2025 · NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD · Persbericht

11 april 2025 · Lucid Diagnostics Announces Closing of Public Offering of Common Stock · Persbericht

10 april 2025 · Lucid Diagnostics Announces Pricing of Public Offering of Common Stock · Persbericht

9 april 2025 · Lucid Diagnostics Announces Proposed Public Offering of Common Stock · Persbericht

3 april 2025 · Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference · Persbericht

27 maart 2025 · Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology · Persbericht

25 maart 2025 · PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

24 maart 2025 · Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

20 maart 2025 · Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening · Persbericht

18 maart 2025 · Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication · Persbericht

13 maart 2025 · Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test · Persbericht

11 maart 2025 · PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 · Persbericht

10 maart 2025 · Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 · Persbericht

5 maart 2025 · Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering · Persbericht

4 maart 2025 · Lucid Diagnostics Announces $15.3 Million Registered Direct Offering · Persbericht

10 september 2024 · Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress · Persbericht

3 september 2024 · Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health · Persbericht

20 augustus 2024 · Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer · Persbericht

Mijn selecties